Pharmaceutical Executive
Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.
Pharm Exec's 2011 Emerging Pharma Leaders program convened in New York on Oct. 6 for a gathering of some of the best minds in the industry under age 45—where we recognize 30 executives from diverse backgrounds who hope to make a difference as the industry grapples with a future that is rift by uncertainty. With our cohost Cegedim Relationship Management, the day began with a Cegedim sponsored roundtable discussion on "lean management" principles and ended with a dinner celebration honoring the winners at the rooftop restaurant 220 FIFTH.
Emerging Leaders and Pharm Exec editors mingle at the outdoor cocktail reception.
Richard Gliklich, CEO, Outcome
Cegedim's Angela Miccoli, left, with Leigh-Ann Durant of EMD Serono
EPL Jessica Monroe of Johnson & Johnson with her husband Todd
Cegedim's Angela Miccoli with Soma Gupta of Pfizer
Angela Miccoli, President of the Americas for Cegedim, along with Editor-in-Chief William Looney, presented each of the Emerging Leaders with an award and a plaque incorporating their career profiles published in the June issue of Pharm Exec. The dinner also featured a guest speaker: Dr. Richard Gliklich, Professor at the Harvard Medical School and founder of Outcome Inc., a leader in the development of patient registries and other tools to build an observational database on drugs. He noted as a key trend for the future the growing size of trial data sets, whose veracity should be accompanied by "a healthy respect for their limitations" in guiding therapy decisions that will affect millions of patients—our industry's key constituency. – Jeff Schindler, Managing Editor
Cegedim's Angela Miccoli with David Stern of EMD Serono
L to R: Jeff Schindler, Managing Editor; Dave Esola, GM, Pharma/Science group; William Looney, Editor-in-Chief; and Jay Berfas, Group Publisher, Pharm Exec
Cegedim's Angela Miccoli with Steven Blum of Forest Laboratories
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.